Regular
NAV (18-Jun-25)
Returns (Since Inception)
Fund Size
₹1,062 Cr
Expense Ratio
2.25%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+18.56%
+14.51% (Cat Avg.)
3 Years
+27.38%
+25.57% (Cat Avg.)
5 Years
+21.68%
+21.51% (Cat Avg.)
10 Years
+11.83%
+14.06% (Cat Avg.)
Since Inception
+14.93%
— (Cat Avg.)
Equity | ₹1,033.83 Cr | 97.33% |
Others | ₹28.36 Cr | 2.67% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹110.89 Cr | 10.44% |
Cipla Ltd | Equity | ₹58.63 Cr | 5.52% |
Dr Reddy's Laboratories Ltd | Equity | ₹49.55 Cr | 4.66% |
Procter & Gamble Health Ltd | Equity | ₹46.15 Cr | 4.34% |
Ajanta Pharma Ltd | Equity | ₹43.39 Cr | 4.09% |
Glenmark Pharmaceuticals Ltd | Equity | ₹40.11 Cr | 3.78% |
Apollo Hospitals Enterprise Ltd | Equity | ₹38.72 Cr | 3.65% |
Divi's Laboratories Ltd | Equity | ₹37.03 Cr | 3.49% |
Fortis Healthcare Ltd | Equity | ₹32.84 Cr | 3.09% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹32.34 Cr | 3.04% |
Jupiter Life Line Hospitals Ltd | Equity | ₹31.35 Cr | 2.95% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹29.45 Cr | 2.77% |
Aurobindo Pharma Ltd | Equity | ₹28.7 Cr | 2.70% |
Gland Pharma Ltd | Equity | ₹28.59 Cr | 2.69% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹28.35 Cr | 2.67% |
Net Current Assets | Cash | ₹28.25 Cr | 2.66% |
Cohance Lifesciences Ltd | Equity | ₹28.13 Cr | 2.65% |
Lupin Ltd | Equity | ₹27.41 Cr | 2.58% |
Caplin Point Laboratories Ltd | Equity | ₹26.83 Cr | 2.53% |
Ipca Laboratories Ltd | Equity | ₹21.89 Cr | 2.06% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹21.57 Cr | 2.03% |
Alkem Laboratories Ltd | Equity | ₹20.39 Cr | 1.92% |
Zydus Lifesciences Ltd | Equity | ₹20.26 Cr | 1.91% |
Global Health Ltd | Equity | ₹18.39 Cr | 1.73% |
Pfizer Ltd | Equity | ₹17.41 Cr | 1.64% |
Marksans Pharma Ltd | Equity | ₹17.41 Cr | 1.64% |
Metropolis Healthcare Ltd | Equity | ₹16.8 Cr | 1.58% |
Sequent Scientific Ltd | Equity | ₹16.71 Cr | 1.57% |
Windlas Biotech Ltd | Equity | ₹13.8 Cr | 1.30% |
Torrent Pharmaceuticals Ltd | Equity | ₹13.6 Cr | 1.28% |
Vijaya Diagnostic Centre Ltd | Equity | ₹13.39 Cr | 1.26% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹12.54 Cr | 1.18% |
Syngene International Ltd | Equity | ₹11.64 Cr | 1.10% |
Alembic Pharmaceuticals Ltd | Equity | ₹11.31 Cr | 1.06% |
Jubilant Pharmova Ltd | Equity | ₹10.53 Cr | 0.99% |
Acutaas Chemicals Ltd | Equity | ₹10.5 Cr | 0.99% |
Emcure Pharmaceuticals Ltd | Equity | ₹9.31 Cr | 0.88% |
Laxmi Dental Ltd | Equity | ₹9.04 Cr | 0.85% |
Rainbow Childrens Medicare Ltd | Equity | ₹8.14 Cr | 0.77% |
Sai Life Sciences Ltd | Equity | ₹7.6 Cr | 0.72% |
Orchid Pharma Ltd | Equity | ₹7.55 Cr | 0.71% |
Concord Biotech Ltd | Equity | ₹5.63 Cr | 0.53% |
Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.11 Cr | 0.01% |
Large Cap Stocks
27.30%
Mid Cap Stocks
27.63%
Small Cap Stocks
41.55%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,023.34 Cr | 96.34% |
Basic Materials | ₹10.5 Cr | 0.99% |
Standard Deviation
This fund
15.78%
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
1.05
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since May 2022
ISIN | INF789F01695 | Expense Ratio | 2.25% | Exit Load | 1.00% | Fund Size | ₹1,062 Cr | Age | 25 years 11 months | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹321.02 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹321.02 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹108.88 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹108.88 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹331.66 Cr | 24.2% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹331.66 Cr | 26.4% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹10.25 Cr | 12.4% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹434.55 Cr | 13.7% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹434.55 Cr | 11.8% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹1704.87 Cr | 24.6% |
Total AUM
₹3,29,939 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk